RAPT Therapeutics Statistics
Share Statistics
RAPT Therapeutics has 34.96M shares outstanding. The number of shares has increased by 1.47% in one year.
| Shares Outstanding | 34.96M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.57M |
| Failed to Deliver (FTD) Shares | 39.22K |
| FTD / Avg. Volume | 7.23% |
Short Selling Information
The latest short interest is 2.67M, so 7.63% of the outstanding shares have been sold short.
| Short Interest | 2.67M |
| Short % of Shares Out | 7.63% |
| Short % of Float | 8.73% |
| Short Ratio (days to cover) | 9.95 |
Valuation Ratios
The PE ratio is -8.16 and the forward PE ratio is -0.92.
| PE Ratio | -8.16 |
| Forward PE | -0.92 |
| PS Ratio | 0 |
| Forward PS | 41.5 |
| PB Ratio | 6.48 |
| P/FCF Ratio | -9.7 |
| PEG Ratio | n/a |
Enterprise Valuation
RAPT Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.41 |
| Quick Ratio | 7.41 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.64 |
| Cash Flow / Debt | -39.64 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -82.54%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.67% |
| Return on Capital (ROIC) | -82.54% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.67M |
| Employee Count | 70 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -95.38% in the last 52 weeks. The beta is 0.32, so RAPT Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | -95.38% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 33.86 |
| Average Volume (20 Days) | 542.41K |
Income Statement
In the last 12 months, RAPT Therapeutics had revenue of $0 and earned -$116.80M in profits. Earnings per share was $-3.05.
| Revenue | 0 |
| Gross Profit | -3.55M |
| Operating Income | -127.06M |
| Net Income | -116.80M |
| EBITDA | -125.85M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.05 |
Balance Sheet
The company has $47.48M in cash and $6.91M in debt, giving a net cash position of $40.57M.
| Cash & Cash Equivalents | 47.48M |
| Total Debt | 6.91M |
| Net Cash | 40.57M |
| Retained Earnings | -484.68M |
| Total Assets | 108.47M |
| Working Capital | 92.24M |
Cash Flow
In the last 12 months, operating cash flow was -$97.05M and capital expenditures -$1.13M, giving a free cash flow of -$98.17M.
| Operating Cash Flow | -97.05M |
| Capital Expenditures | -1.13M |
| Free Cash Flow | -98.17M |
| FCF Per Share | -2.56 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RAPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -335.16% |
| FCF Yield | -307.99% |
Analyst Forecast
The average price target for RAPT is $4, which is 339.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 339.6% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
Scores
| Altman Z-Score | -8 |
| Piotroski F-Score | 3 |